Imerys

FY20: recovery in end-markets gaining pace

19/02/21 -"Imerys published FY20 results which were better than expected. It saw a catch-up in volume demand by Q4 and maintained a positive price mix. Well managed opex resulted in an EBITDA margin at 18% in ..."

PDF page sample
Pages
53
Language
English
Published on
19/02/21
Download
You may also be interested by these reports :
01/09/26
Dormakaba delivered a resilient FY25/26, with 3.0% organic growth, a record 16.1% adjusted EBITDA margin, and stronger H2 momentum. Management guides ...
20/08/26
Our DCF increases as we raise our assumptions following a solid 2Q26 that demonstrated resilience in a still-challenging environment. The group ...
19/08/26
Geberit delivered a strong Q2 2026, with revenue of CHF 838m, c. 4% above consensus, and local-currency growth of 8.8%, versus 4.7% expected. EBITDA ...
19/08/26
Geberit delivered a strong Q2, with sales and EBITDA above expectations and local-currency growth of 8.8%, largely driven by volumes. Margins ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO